Holen Sie sich die Stockscreener-App
0.0002
33.64%
-0.0601
Paxmedica Inc Aktie (PXMD) Neueste Nachrichten
Contrasting Calliditas Therapeutics AB (publ) (NASDAQ:CALT) & PaxMedica (NASDAQ:PXMD) - Defense World
Delisting of Securities from The Nasdaq Stock Market - The Manila Times
Comparing Intra-Cellular Therapies (NASDAQ:ITCI) and PaxMedica (NASDAQ:PXMD) - Defense World
Kuvatris Therapeutics Renames, Cancels Shares Amid Restructuring - AInvest
PaxMedica Renames to Kuvatris, Cancels Shares - TipRanks
PaxMedica Provides Company Update and Continues to Advance PAX-101 Regulatory Strategy - marketscreener.com
Press Release Distribution & PR Platform - ACCESS Newswire
PaxMedica announces board resignations amid transition By Investing.com - Investing.com Canada
PaxMedica announces board resignations amid transition - Investing.com Australia
PaxMedica Announces Board Chairman Resignation Amid Transition - TipRanks
PaxMedica Holds Important FDA Type-B Meeting to Review PAX-101 Pivotal Trial Data - ACCESS Newswire
PaxMedica Announces Resignation of Key Executives - TipRanks
PaxMedica Reports First Patient Treated with PAX-101 for Fatal African Sleeping Sickness Infection - ACCESS Newswire
PaxMedica Announces First Patent Allowance for Suramin Intranasal Formulation in the treatment of Autism Spectrum Disorder and Other Conditions - ACCESS Newswire
Craft Capital Management Announces Pricing of Initial Public Offering for PaxMedica, Inc. - ACCESS Newswire
PaxMedica Secures Immediate Exercise of Warrants - ACCESS Newswire
BioMedNewsBreaks – PaxMedica Inc. (PXMD) Secures Patent Approval in China for Autism Treatment - Financial Content
Autism Prevalence Surges Globally, Raising Concerns Among Healthcare Experts - FinancialContent
BioMedNewsBreaks — PaxMedica Inc. (PXMD) Announces Immediate Exercise of Warrants to Total Approximately $884K | Dow Theory Letters - FinancialContent
BioMedNewsBreaks — PaxMedica Inc. (PXMD) Intensifying Efforts to Achieve Significant Program Milestones - FinancialContent
Researchers Say Brain ‘Overgrowth’ Could Contribute to Autism Development - FinancialContent
Silicon Valley - FinancialContent
PaxMedica (NASDAQ: PXMD) Seeking to Qualify for Neglected Tropical Disease Priority Review Voucher - Barchart.com
PaxMedica Files Nasdaq Delisting Appeal Notice and Prepares for Upcoming FDA Meeting on PAX-101 - Yahoo Finance
PXMD Stock Price and Chart — OTC:PXMD - TradingView
PaxMedica's CEO and Malawi Health Official Discuss Urgent Medical Crisis in Bell2Bell Podcast - Yahoo Finance
As Autism Cases Rise, Biopharma Springs Into Action - BioSpace
PaxMedica Responds to Emergency Request for IV Suramin and Commits to Provide Immediate Access to PAX-101 - GlobeNewswire
PaxMedica Receives Emergency Request for IV Suramin from - GlobeNewswire
Why Is PaxMedica (PXMD) Stock Up 93% Today? - InvestorPlace
PaxMedica Achieves Key Milestone in the Development of - GlobeNewswire
PaxMedica Updated Company Presentation Highlighting Innovations in Autism Spectrum Disorder Treatments - GlobeNewswire
PaxMedica Accelerates RSU Vesting for Top Executives - TipRanks
PaxMedica (NASDAQ: PXMD) Dedicated to Enhancing Quality of Life for Individuals with ASD - The Globe and Mail
PaxMedica Releases Fireside Chat Video with CEO Howard Weisman - StreetInsider
PaxMedica (NASDAQ: PXMD) Closes on Public Offering Reaching Estimated $7M - The Globe and Mail
Penny Stocks To Buy? 5 To Watch Right Now - PennyStocks.com
PaxMedica News of FDA Type-B Meeting Shared in Audio Broadcast - Yahoo Finance
Why Is PaxMedica (PXMD) Stock Down 40% Today? - InvestorPlace
PaxMedica Releases Q3 2023 Financial Report, Corporate Update - Yahoo Finance
What's Going On With PaxMedica Stock Today? - Benzinga
What LIFW, PXMD, and NVOS have in common - StocksToTrade
PaxMedica Announces Publication of Its Autism Spectrum Disorder Phase 2 Study Results in Peer-reviewed Journal - Yahoo Finance
PaxMedica Engages Bourne Partners to Explore Future Monetization of Potential Priority Review Voucher (PRV) - GlobeNewswire
PaxMedica (NASDAQ: PXMD) Reports on 1-for-17 Reverse Stock Split - The Globe and Mail
PaxMedica Announces 1-for-17 Reverse Stock Split - Yahoo Finance
Thinking about buying stock in Nextplay Technologies, ABVC Biopharma, PaxMedica, Mustang Bio, or NXU Inc.? - MarketScreener
Why Is PaxMedica (PXMD) Stock Up Today? - TradingView
PaxMedica Announces Gold Sponsorship of The BRAIN Foundation's Synchrony Symposia 2023 - Yahoo Finance
PaxMedica, Inc. Announces Second Quarter 2023 Financial Results and Business Update - Yahoo Finance
PaxMedica seeks SAHPRA approval to initiate ASD therapy trial - Clinical Trials Arena
PaxMedica Submits Clinical Trial Request in Autism Spectrum Disorder - GlobeNewswire
PaxMedica and PoloMar to investigate emodin in ASD trial - Clinical Trials Arena
PaxMedica Enters Research Collaboration Agreement With - GlobeNewswire
PaxMedica Completes HAT-301 Registrational Trial for PAX-101 - GlobeNewswire
PaxMedica Announces NASDAQ Closing Bell Ringing to Celebrate Initial Public Offering and Autism Awareness Month - Yahoo Finance
5 Short Squeeze Stocks To Watch: Getty Images, PaxMedica, A Mental Health Care Company And More By Benzinga - Investing.com UK
PaxMedica, Inc. Provides Business Update and Reports Fourth Quarter 2022 Financial Results - Yahoo Finance
Best Penny Stocks To Buy? 3 Short Squeeze Stocks To Watch - Penny Stocks
Autistic Disorder Clinical Trial Pipeline Insights Featuring 25+ Companies | DelveInsight - GlobeNewswire
PaxMedica Signs $3.2 Million Funding Deal With Lind Global Partners; Shares Rise - MarketScreener
PaxMedica Releases 2022 Shareholder Letter - Yahoo Finance
PaxMedica to Present at the Jan 26th Virtual Investor Summit Microcap Event - Yahoo Finance
Ambrx Biopharma, PaxMedica And 3 More Short Squeeze Stocks That Could Soar This Week - Benzinga
PaxMedica, Inc. Launches Updated Corporate Website at - GlobeNewswire
PaxMedica to Present at the Benchmark Company’s Upcoming Discovery One-on-One Investor Conference - GlobeNewswire
PaxMedica (PXMD) Stock Soared 41% on a $20 Mln Funding Deal - AskTraders.com
PaxMedica, Inc. Enters Into Committed Equity Investment Agreement for up to $20 Million With Lincoln Park Capital - GlobeNewswire
PaxMedica Initiates Clinical Program to Advance PAX-101 Towards FDA Submission - GlobeNewswire
0.96%
1.09%
Kapitalisierung:
|
Volumen (24h):